Cases & Deals

  • Home
  • Practices
  • BioMarin develops gene therapy treatment for PKU

Share

BioMarin develops gene therapy treatment for PKU

May 2019

Client(s) BioMarin Pharmaceutical Inc.

Jones Day is representing BioMarin Pharmaceutical Inc. in its development of a phenylalanine hydroxylase ("PAH") gene therapy treatment for phenylketonuria ("PKU").

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.